Oral Immune-Related Adverse Events - Current Concepts and their Management

被引：3

作者：

Asan, Mohamed Faizal ^{[1
]}

Castelino, Renita Lorina ^{[1
]}

Babu, Subhas G. ^{[1
]}

Rao, Kumuda ^{[1
]}

Pandita, Vaibhav ^{[1
]}

机构：

[1] Nitte Deemed be Univ, AB Shetty Mem Inst Dent Sci, Dept Oral Med & Radiol, Mangalore, Karnataka, India

来源：

ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING | 2021年 / 8卷 / 06期

基金：

英国科研创新办公室;

关键词：

Immune-related adverse events; immunotherapy; oral mucositis; quality of life; LEVEL LASER THERAPY; CHECKPOINT INHIBITORS; LICHENOID REACTIONS; CANCER; ANTI-PD-1; SAFETY; PEMBROLIZUMAB; IMMUNOTHERAPY; IPILIMUMAB; NIVOLUMAB;

D O I：

10.4103/apjon.apjon-2136

中图分类号：

R47 [护理学];

学科分类号：

1011 ;

摘要：

Recent advent of immune checkpoint inhibitors (ICIs) have made significant improvement in the treatment outcome of cancer patients. They are also known to increase the overall survival in many malignancies. They target key immune checkpoints, acting on the cytotoxic T-lymphocyte antigen-4, programmed death-1 (PD-1), and PD-1 ligand 1 pathways. ICIs are effective in cancer therapy, but also possess various adverse effects that are termed together as immune-related adverse events (irAEs). Information focusing only on the oral reactions of irAEs is scanty in the literature. Therefore, we performed a computerized database search in PubMed and Google Scholar to identify and collect data regarding the oral adverse effects of ICIs. The early recognition of oral irAEs and appropriative intervention may help in improving the quality of life in patients. This paper presents a brief review of oral irAEs and their management.

引用

页码：604 / 609

页数：6

共 50 条

[41] Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies [J].

Sibaud, Vincent ;

Meyer, Nicolas ;

Lamant, Laurence ;

Vigarios, Emmanuelle ;

Mazieres, Julien ;

Delord, Jean Pierre .

CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) :254-263

[42] Efficacy and Safety of an Intraoral Electrostimulation Device for Xerostomia Relief A Multicenter, Randomized Trial [J].

Strietzel, Frank P. ;

Lafaurie, Gloria I. ;

Bautista Mendoza, Gloria R. ;

Alajbeg, Ivan ;

Pejda, Slavica ;

Vuletic, Lea ;

Mantilla, Ruben ;

Falcao, Denise P. ;

Leal, Soraya C. ;

Barreto Bezerra, Ana C. ;

Tran, Simon D. ;

Menard, Henri A. ;

Kimoto, Suguru ;

Pan, Shaoxia ;

Martin-Granizo, Rafael A. ;

Maniegas Lozano, M. Lourdes ;

Zunt, Susan L. ;

Krushinski, Cheryl A. ;

Melilli, Dario ;

Campisi, Giuseppina ;

Paderni, Carlo ;

Dolce, Sonia ;

Yepes, Juan F. ;

Lindh, Liselott ;

Koray, Meltem ;

Mumcu, Gonca ;

Elad, Sharon ;

Zeevi, Itai ;

Aldape Barrios, Beatriz C. ;

Lopez Sanchez, Rodrigo M. ;

Beiski, Ben Z. ;

Wolff, Andy ;

Konttinen, Yrjo T. .

ARTHRITIS AND RHEUMATISM, 2011, 63 (01) :180-190

[43] Nivolumab-induced sialadenitis [J].

Takahashi, Saeko ;

Chieko, Xu ;

Sakai, Tetsuya ;

Hirose, Shigemichi ;

Nakamura, Morio .

RESPIROLOGY CASE REPORTS, 2018, 6 (05)

[44] Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab [J].

Topalian, Suzanne L. ;

Sznol, Mario ;

McDermott, David F. ;

Kluger, Harriet M. ;

Carvajal, Richard D. ;

Sharfman, William H. ;

Brahmer, Julie R. ;

Lawrence, Donald P. ;

Atkins, Michael B. ;

Powderly, John D. ;

Leming, Philip D. ;

Lipson, Evan J. ;

Puzanov, Igor ;

Smith, David C. ;

Taube, Janis M. ;

Wigginton, Jon M. ;

Kollia, Georgia D. ;

Gupta, Ashok ;

Pardoll, Drew M. ;

Sosman, Jeffrey A. ;

Hodi, F. Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) :1020-+

[45] A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects [J].

Utsunomiya, Akira ;

Oyama, Noritaka ;

Iino, Shiro ;

Baba, Natsuki ;

Chino, Takenao ;

Utsunomiya, Natsuko ;

Hasegawa, Minoru .

CASE REPORTS IN DERMATOLOGY, 2018, 10 (01) :1-6

[46] Microbiota and their role in the pathogenesis of oral mucositis [J].

Vanhoecke, B. ;

De Ryck, T. ;

Stringer, A. ;

Van de Wiele, T. ;

Keefe, D. .

ORAL DISEASES, 2015, 21 (01) :17-30

[47] Localized Delivery of Amifostine Enhances Salivary Gland Radioprotection [J].

Varghese, J. J. ;

Schmale, I. L. ;

Mickelsen, D. ;

Hansen, M. E. ;

Newlands, S. D. ;

Benoit, D. S. W. ;

Korshunov, V. A. ;

Ovitt, C. E. .

JOURNAL OF DENTAL RESEARCH, 2018, 97 (11) :1252-1259

[48] Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis [J].

Wang, Daniel Y. ;

Salem, Joe-Elie ;

Cohen, Justine V. ;

Chandra, Sunandana ;

Menzer, Christian ;

Ye, Fei ;

Zhao, Shilin ;

Das, Satya ;

Beckermann, Kathryn E. ;

Ha, Lisa ;

Rathmell, W. Kimryn ;

Ancell, Kristin K. ;

Balko, Justin M. ;

Bowman, Caitlin ;

Davis, Elizabeth J. ;

Chism, David D. ;

Horn, Leora ;

Long, Georgina V. ;

Carlino, Matteo S. ;

Lebrun-Vignes, Benedicte ;

Eroglu, Zeynep ;

Hassel, Jessica C. ;

Menzies, Alexander M. ;

Sosman, Jeffrey A. ;

Sullivan, Ryan J. ;

Moslehi, Javid J. ;

Johnson, Douglas B. .

JAMA ONCOLOGY, 2018, 4 (12) :1721-1728

[49] Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy [J].

Warner, Blake M. ;

Baer, Alan N. ;

Lipson, Evan J. ;

Allen, Clint ;

Hinrichs, Christian ;

Rajan, Arun ;

Pelayo, Eileen ;

Beach, Margaret ;

Gulley, James L. ;

Madan, Ravi A. ;

Feliciano, Josephine ;

Grisius, Margaret ;

Long, Lauren ;

Powers, Astin ;

Kleiner, David E. ;

Cappelli, Laura ;

Alevizos, Ilias .

ONCOLOGIST, 2019, 24 (09) :1259-1269

[50] Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study [J].

Yoon, Soo-Young ;

Han, Jae Joon ;

Baek, Sun Kyung ;

Kim, Hong Jun ;

Maeng, Chi Hoon .

LUNG CANCER, 2020, 147 :21-25

← 1 2 3 4 5 →